Atara Biotherapeutics, Inc. (ATRA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Atara Biotherapeutics reported revenue of $120.8M, down 6.3% from $128.9M the year before. Net income was $32.7M (a 27.1% net margin), or $2.57 per diluted share. Gross margin was 29.7% and operating margin was 29.7%. Operating activities generated -$50.9M of cash. At fiscal year end, Atara Biotherapeutics held $20.2M in total assets against $58.7M in total liabilities, including $8.5M of cash and equivalents.
Open the full interactive Atara Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Atara Biotherapeutics Key Stats
| Share Price | $9.31 |
|---|---|
| Market Cap | $139.9M |
| P/E Ratio | 3.6 |
| Revenue YoY Growth | -6.3% |
| 52-Week Range | $4.18 – $18.09 |
| Shares Outstanding | 15.0 million (basic, 2026 Q2) |
Atara Biotherapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8.6M | $128.9M | $120.8M |
| Cost of Goods Sold | — | — | — | $284.6M | $212.4M | $84.9M |
| Gross Profit | — | — | — | -$276.0M | -$83.4M | $35.9M |
| Operating Income | -$309.1M | -$340.5M | -$280.5M | -$276.0M | -$83.4M | $35.9M |
| Pre-Tax Income | -$306.6M | -$340.1M | -$228.3M | -$276.1M | -$85.4M | $32.7M |
| Income Tax | $15,000 | $46,000 | $12,000 | $15,000 | -$12,000 | $31,000 |
| Net Income | -$306.6M | -$340.1M | -$228.3M | -$276.1M | -$85.4M | $32.7M |
| Diluted EPS | -$103.75 | -$90.75 | -$56.00 | -$65.25 | -$11.41 | $2.57 |
Atara Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.5M | $1.6M | $516,000 | $630,000 |
| Net Income | -$4.3M | -$3.4M | -$4.1M | -$4.8M |
| Diluted EPS | -$0.32 | -$0.27 | -$0.29 | -$0.32 |
Atara Biotherapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $200.4M | $106.1M | $92.9M | $25.8M | $25.0M | $8.5M |
| Current Assets | $523.3M | $384.6M | $295.1M | $101.9M | $64.9M | $12.2M |
| Total Assets | $588.1M | $468.1M | $376.4M | $165.5M | $109.1M | $20.2M |
| Current Liabilities | $82.9M | $105.8M | $78.9M | $142.2M | $134.6M | $14.9M |
| Total Liabilities | $125.8M | $188.5M | $249.8M | $264.7M | $206.4M | $58.7M |
| Shareholders' Equity | $462.3M | $279.6M | $126.6M | -$99.2M | -$97.3M | -$38.5M |
Atara Biotherapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$180.8M | -$220.5M | -$270.4M | -$193.0M | -$68.7M | -$50.9M |
| Cash From Investing | -$120.7M | $22.3M | $203.0M | $123.9M | $8.6M | $18.1M |
| Cash From Financing | $427.6M | $103.9M | $53.1M | $2.0M | $59.3M | $16.1M |
| Free Cash Flow | -$185.3M | -$231.1M | -$274.6M | -$194.2M | -$69.0M | -$50.9M |
Figures from Atara Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Atara Biotherapeutics financials page for every line item.
Atara Biotherapeutics Company Profile
| Ticker | ATRA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Thousand Oaks, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001604464 |
Frequently Asked Questions
What was Atara Biotherapeutics' revenue in fiscal 2025?
Atara Biotherapeutics (ATRA) reported revenue of $120.8M for fiscal 2025.
What is Atara Biotherapeutics' annual revenue history?
Atara Biotherapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $8.6M; 2024: $128.9M; 2025: $120.8M.
What was Atara Biotherapeutics' net income in fiscal 2025?
Atara Biotherapeutics reported net income of $32.7M for fiscal 2025.
What was Atara Biotherapeutics' earnings per share (EPS) in fiscal 2025?
Atara Biotherapeutics' diluted EPS was $2.57 for fiscal 2025 (adjusted for any later stock splits).
What was Atara Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Atara Biotherapeutics reported revenue of $630,000.
How many shares of Atara Biotherapeutics are outstanding?
Atara Biotherapeutics reported a weighted average of 15.0 million basic shares outstanding in 2026 Q2.
What is Atara Biotherapeutics' market cap?
Based on its latest closing price, Atara Biotherapeutics (ATRA) has a market capitalization of about $139.9M.
When does Atara Biotherapeutics' fiscal year end?
Atara Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Atara Biotherapeutics headquartered?
Atara Biotherapeutics lists its business address in Thousand Oaks, California in its SEC filings.
Atara Biotherapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →